Glucagon-like peptide-1 (Glp-1) analogs (also known as incretin mimetics) are a relatively new class of injectable drugs indicated for the treatment of type 2 diabetes. The drugs are normally prescribed for patients who have not been able to control their condition with tablet medication. In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.
Victoza (Liraglutide); taken once daily, Trulicity (Dulaglutide); taken once weekly, Lyxumia (lixisenatide); taken once daily, Byetta (Exenatide); taken twice daily, and Bydureon (Exenatide); taken once weekly are some of the glucagon-like peptide-1 (Glp-1) analogs available in the United Kingdom for type 2 diabetic patients.
Market Dynamics:
Increasing prevalence of diabetes worldwide is expected to propel the growth of the glucagon-like peptide-1 (Glp-1) analogs market. For instance, according to the Centers for Disease Control and Prevention’s National Diabetes Statistics Report (2020), more than 34 million people in the United States have diabetes (around one in ten), and approximately 90-95% of them have type 2 diabetes. Moreover, increasing awareness among physicians regarding benefits of glucagon-like peptide-1 (Glp-1) analogs over conventional anti-diabetic medication is also expected to augment the growth of the glucagon-like peptide-1 (Glp-1) analogs market.
Furthermore, increasing product launches and approvals are expected to drive the growth of the glucagon-like peptide-1 (Glp-1) analogs market. For instance, in September 2019, the United States Food and Drug Administration (FDA) approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the U.S. that does not need to be injected. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes.
Asia-Pacific is expected to witness robust growth in the market due to increase in number of cases of diabetes and related disorders and increasing number of generic drugs in the region.
Competitive Analysis:
Major players operating in the glucagon-like peptide-1 (Glp-1) analogs market are Hoffmann-La Roche Ltd, GlaxoSmithKline, AstraZeneca, Sanofi, Eli-Lilly and Company, and Novo Nordisk.
In April 2019, Novo Nordisk announced a settlement with Teva Pharmaceuticals (Teva) giving the company at least four years before it has to compete with biosimilar versions of its diabetes injectable Victoza (liraglutide). Victoza is an injectable drug used for the treatment of type 2 diabetes and obesity, developed by Danish pharmaceutical firm Novo Nordisk.
https://www.coherentmarketinsights.com/ongoing-insight/glucagon-like-peptide-1-analogs-market-1252
No comments:
Post a Comment